News

The National Institute for Health and Care Excellence14h
NHS 10 Year Plan empowers NICE to get patients better care, faster
The 10-Year Health Plan marks a significant step forward in building an NHS that is faster, fairer and fit for the future. At NICE, we’re ready to deliver - using our expanded remit to accelerate ...
The National Institute for Health and Care Excellence2d
NICE welcomes the inclusion of measures for equal treatment of medicines and health technologies
The new approach will ensure that high-impact devices, diagnostics and digital tools recommended by NICE, that meet the most urgent needs, are nationally reimbursed and made available across the NHS - ...
The National Institute for Health and Care Excellence9d
Harnessing digital innovation for children's mental health
In this guest blog, Dale Greenwood, mental health lead for East London NHS Foundation Trust, shares how his trust implemented ...
National Institute for Health and Care Excellence15d
Overview | Tislelizumab for treating advanced non-small-cell lung cancer after platinum-based chemotherapy (terminated appraisal) | Guidance | NICE
NICE is unable to make a recommendation on tislelizumab (Tevimbra) for treating advanced non-small-cell lung cancer after platinum-based chemotherapy in adults. This is because BeiGene withdrew its ...
National Institute for Health and Care Excellence15d
Overview | Topical antimicrobial dressings for locally infected leg ulcers: late-stage assessment | Guidance | NICE
Late stage assessment (LSA) guidance on topical antimicrobial dressings for locally infected leg ulcers. Last reviewed: 19 June 2025 Guidance development process LSA guidance evaluates categories of ...
National Institute for Health and Care Excellence15d
Overview | Atezolizumab for adjuvant treatment of resected non-small-cell lung cancer | Guidance | NICE
Evidence-based recommendations on atezolizumab (Tecentriq) for the adjuvant treatment of resected non-small-cell lung cancer in adults. Last reviewed: 19 June 2025 Next review: This guidance will be ...
National Institute for Health and Care Excellence15d
Resource impact summary report | Tools and resources | Atezolizumab for adjuvant treatment of resected non-small-cell lung cancer | Guidance | NICE
Capacity impact The capacity impact of this topic will have been realised while the treatment has been in the Cancer Drugs Fund. So, no significant change in capacity is anticipated. Localities can ...
National Institute for Health and Care Excellence15d
Information for the public | Topical antimicrobial dressings for locally infected leg ulcers: late-stage assessment | Guidance | NICE
You should have access to a topical antimicrobial dressing that is clinically appropriate and meets your needs and preferences. You and your healthcare professional should decide together which ...
National Institute for Health and Care Excellence15d
4 Committee members | Topical antimicrobial dressings for locally infected leg ulcers: late-stage assessment | Guidance | NICE
4 Committee members This topic was considered by NICE's medical technologies advisory committee, which is a standing advisory committee of NICE. Committee members are asked to declare any interests in ...
National Institute for Health and Care Excellence15d
2 The technology | Topical antimicrobial dressings for locally infected leg ulcers: late-stage assessment | Guidance | NICE
Topical antimicrobial dressings are dressings that aim to decrease the microbial burden of the wound. How they work varies, with some dressings designed to release the antimicrobial agent into the ...
National Institute for Health and Care Excellence15d
2 Information about atezolizumab - NICE
Atezolizumab (Tecentriq, Roche) is indicated for 'adjuvant treatment following complete resection and platinum-based chemotherapy for adult patients with NSCLC with a high risk of recurrence whose ...